IP Library Granted Patent US 11,390,888
Granted Patent B2
US 11,390,888 · App. 16/816,172 · Granted Jul 19, 2022

Methods for genomic integration

Inventors: Andrew Horwitz (Emeryville, CA); Kristy Michelle Hawkins (Emeryville, CA); Max Schubert (Emeryville, CA); Wayne Szeto (Emeryville, CA)
Assignee: AMYRIS, INC.
C12N15/907C12N15/111C12N15/902C12Q1/6897C12N2310/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,390,888
App. No.
16/816,172
Granted
Jul 19, 2022
Kind
B2
Abstract

Provided herein are methods of integrating one or more exogenous nucleic acids into one or more selected target sites of a host cell genome. in certain embodiments, the methods comprise contacting the host cell genome with one or more integration polynucleotides comprising an exogenous nucleic acid to be integrated into a genomic target site, a nuclease capable of causing a break at the genomic target site, and a linear nucleic acid capable of homologous recombination with itself or with one or more additional linear nucleic acids contacted with the population of cells, whereupon said homologous recombination results in formation of a circular extrachromosomal nucleic acid comprising a coding sequence for a selectable marker. in some embodiments, the methods further comprise selecting a host cell that expresses the selectable marker.

Claims (6)

1. A composition comprising:

(a) a nucleic acid comprising a coding sequence for a site-specific nuclease; and

(b) a linear nucleic acid comprising two internal homology regions that upon introduction into a host cell are capable of homologously recombining with each other in the host cell, whereupon homologous recombination of the internal homology regions results in formation of a circular nucleic acid comprising a coding sequence for a selectable marker, and further wherein the linear nucleic acid is linear prior to introduction into the host cell.

2. A host cell comprising the composition of claim 1 .

3. A cell culture composition comprising a cell culture medium and the host cell of claim 2 .

4. The cell culture composition of claim 3 , further comprising a compound that selects for expression of the selectable marker.

Assignments (7)
SECURITY INTEREST Recorded May 24, 2024
From: AMYRIS, INC.
To: EUAGORE, LLC
Reel/Frame 067528/0467 →
SECURITY INTEREST Recorded Aug 17, 2023
From: AMYRIS, INC.; AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; APRINNOVA, LLC; AMYRIS-OLINKA, LLC; ONDA BEAUTY INC.; UPLAND 1 LLC; AMYRIS ECO-FAB LLC; CLEAN BEAUTY 4U HOLDINGS, LLC; AMYRIS CLEAN BEAUTY LATAM LTDA; INTERFACES INDUSTRIA E COMERCIA DE COSMETICOS LTDA; AMYRIS BIOTECHNOLOGIA DO BRASIL LTDA; AMYRIS EUROPE TRADING B.V. (NETHERLANDS); AMYRIS BIO PRODCUTS PORTUGAL, UNIPESSOAL, LDA; BEAUTY LABS INTERNATIONAL LIMITED; AMYRIS UK TRADING LIMITED
To: EUAGORE, LLC
Reel/Frame 064619/0778 →
SECURITY INTEREST Recorded Aug 3, 2023
From: AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; AMYRIS, INC.
To: MUIRISC, LLC
Reel/Frame 064492/0518 →
RELEASE OF SECURITY INTEREST Recorded Jan 6, 2023
From: NAXYRIS S.A.
To: AMYRIS, INC.
Reel/Frame 062310/0378 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2022
From: HORWITZ, ANDREW; HAWKINS, KRISTY MICHELLE; SCHUBERT, MAX; SZETO, WAYNE
To: AMYRIS, INC.
Reel/Frame 061732/0475 →
SECURITY INTEREST Recorded Oct 18, 2022
From: AMYRIS, INC.
To: FORIS VENTURES, LLC
Reel/Frame 061703/0499 →
SECURITY INTEREST Recorded Apr 28, 2020
From: AMYRIS, INC., AS PARENT
To: NAXYRIS S.A., AS LENDER
Reel/Frame 052518/0474 →
Continuity (6)
Division 16044381 · Jul 24, 2018
Continuation 15261727 · Sep 9, 2016
Continuation 14577997 · Dec 19, 2014
Provisional Application 61937444 · Feb 7, 2014
Provisional Application 61918625 · Dec 19, 2013
Related Publication 20200354746A1 · Nov 12, 2020